For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Empagliflozin - Heart failure
PAD Profile : Empagliflozin - Heart failure
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Eplerenone
- Ivabradine
- Sacubitril/valsartan
- Digoxin
- Spironolactone
- Dapagliflozin
- Metolazone
- Ramipril
- Captopril
- Enalapril maleate
- Lisinopril
- Perindopril erbumine
- Bisoprolol fumarate
- Carvedilol
- Nebivolol
- Candesartan cilexetil
- Losartan potassium
- Valsartan
- Prazosin hydrochloride
- Hydralazine hydrochloride
- Acetazolamide
- Enoximone
- Milrinone lactate
Other Indications
Additional Documents
Committee Recommendations
The Medicines safety Committee has approved the 'Getting the most from your SGLT2 inhibitor (‘gliflozin’) medicine' PIL which can be adapted for use by services.
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves empagliflozin:
- as an option for treating adult chronic heart failure with reduced ejection fraction in addition to standard care (NICE TA773)
- as an option for treating adult chronic heart failure with preserved or mildly reduced ejection fraction in addition to standard care (NICE TA929)
Treatment should be initiated or recommended by a heart failure specialist in patients with a formal diagnosis of heart failure as per NICE guideline on Chronic Heart Failure in adults
Heart Failure specialist defined as:
• Cardiology consultant, specialist, or registrar
• Heart failure specialist nurse
• GP with a specialist interest in heart failure or GP cardiologist
• General physician with heart failure expertise
• Renal physician
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a BLUE information sheet for empagliflozin and dapagliflozin for Adult Heart Failure with reduced ejection fraction (HFrEF) and a place in therapy document for these treatments in patients with Heart Failure.